Rolence Pierre

Colchicine for cardiovascular secondary prevention: evidence from recent trials and meta-analyses

PURPOSE OF REVIEW: Residual inflammatory risk remains an important driver of recurrent vascular events despite contemporary lipid-lowering and antithrombotic therapies. Low-dose colchicine is the first widely available anti-inflammatory therapy to be incorporated into contemporar...